Financials in USD. Standardized financial statements.
A compact view of how Genex Pharmaceutical, Inc. turns revenue into operating income and net income.
| Metric | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 |
|---|---|---|---|---|---|
| Revenue? | $3.24M | $2.44M | $2.49M | $2.35M | $3,483 |
| Revenue Growth? | +32.8% | -2.1% | +6.0% | +67372.0% | 0.0% |
| Cost of Revenue? | $362,715 | $217,479 | $302,246 | $282,646 | $3,784 |
| Gross Profit? | $2.87M | $2.22M | $2.19M | $2.07M | -$301 |
| Gross Margin? | +88.8% | +91.1% | +87.9% | +88.0% | -8.6% |
| Operating Expenses? | $2.41M | $1.37M | $1.27M | $1.08M | -$52,556 |
| Operating Income? | $466,137 | $846,679 | $920,586 | $992,118 | $52,255 |
| EBITDA? | $789,722 | $902,616 | $980,434 | $1.05M | -$48,870 |
| Income Before Tax | $733,586 | $1.03M | $953,366 | $1.01M | $0 |
| Income Tax Expense | $391,037 | $406,912 | $328,352 | $0 | $0 |
| Net Income? | $342,549 | $618,963 | $625,014 | $1.01M | -$52,255 |
| EPS? | $0.02 | $0.03 | $0.04 | $0.06 | $-0.01 |
| Diluted EPS? | $0.02 | $0.03 | $0.04 | $0.06 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality